KR20240131352A - 듀피르페니돈을 이용한 특발성 폐섬유증을 치료하는 방법 - Google Patents

듀피르페니돈을 이용한 특발성 폐섬유증을 치료하는 방법 Download PDF

Info

Publication number
KR20240131352A
KR20240131352A KR1020247022244A KR20247022244A KR20240131352A KR 20240131352 A KR20240131352 A KR 20240131352A KR 1020247022244 A KR1020247022244 A KR 1020247022244A KR 20247022244 A KR20247022244 A KR 20247022244A KR 20240131352 A KR20240131352 A KR 20240131352A
Authority
KR
South Korea
Prior art keywords
treatment
lyt
pirfenidone
subject
tid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247022244A
Other languages
English (en)
Korean (ko)
Inventor
마이클 씨. 첸
에릭 엘렌코
헤더 에이. 파덴
크리스토퍼 씨. 코스
폴 앤드류 포드
줄리 에스. 크롭
카밀라 에스. 그레이엄
라이자 씨. 미치오니
사이먼 존 해치
바룬 가르그
Original Assignee
퓨어테크 엘와이티 100, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 퓨어테크 엘와이티 100, 아이엔씨. filed Critical 퓨어테크 엘와이티 100, 아이엔씨.
Publication of KR20240131352A publication Critical patent/KR20240131352A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247022244A 2022-01-05 2023-01-05 듀피르페니돈을 이용한 특발성 폐섬유증을 치료하는 방법 Pending KR20240131352A (ko)

Applications Claiming Priority (31)

Application Number Priority Date Filing Date Title
US202263296826P 2022-01-05 2022-01-05
US202263296818P 2022-01-05 2022-01-05
US202263296843P 2022-01-05 2022-01-05
US63/296,843 2022-01-05
US63/296,826 2022-01-05
US63/296,818 2022-01-05
US202263326132P 2022-03-31 2022-03-31
US202263326129P 2022-03-31 2022-03-31
US63/326,132 2022-03-31
US63/326,129 2022-03-31
US202263341269P 2022-05-12 2022-05-12
US202263341279P 2022-05-12 2022-05-12
US202263341281P 2022-05-12 2022-05-12
US63/341,281 2022-05-12
US63/341,269 2022-05-12
US63/341,279 2022-05-12
US202263341828P 2022-05-13 2022-05-13
US63/341,828 2022-05-13
US202263352107P 2022-06-14 2022-06-14
US63/352,107 2022-06-14
US202263356653P 2022-06-29 2022-06-29
US63/356,653 2022-06-29
US202263374362P 2022-09-01 2022-09-01
US63/374,362 2022-09-01
US202263403481P 2022-09-02 2022-09-02
US63/403,481 2022-09-02
US202263431530P 2022-12-09 2022-12-09
US63/431,530 2022-12-09
US202263432208P 2022-12-13 2022-12-13
US63/432,208 2022-12-13
PCT/US2023/060185 WO2023133476A1 (en) 2022-01-05 2023-01-05 Methods of treating idiopathic pulmonary fibrosis with deupirfenidone

Publications (1)

Publication Number Publication Date
KR20240131352A true KR20240131352A (ko) 2024-08-30

Family

ID=87074293

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247022244A Pending KR20240131352A (ko) 2022-01-05 2023-01-05 듀피르페니돈을 이용한 특발성 폐섬유증을 치료하는 방법

Country Status (9)

Country Link
US (1) US20240358690A1 (https=)
EP (1) EP4460305A4 (https=)
JP (1) JP2025502023A (https=)
KR (1) KR20240131352A (https=)
AU (1) AU2023205787A1 (https=)
CA (1) CA3239301A1 (https=)
IL (1) IL314022A (https=)
MX (1) MX2024008476A (https=)
WO (1) WO2023133476A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025511066A (ja) * 2022-03-31 2025-04-15 ピュアテック・エル・ワイ・ティ・１００・インコーポレイテッド デューピルフェニドンにより間質性肺疾患ならびに他の線維化介在性肺疾患及び障害を治療する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
WO2009035598A1 (en) * 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
EP4603148A3 (en) * 2018-09-14 2025-10-29 Puretech Lyt 100, Inc. Deuterium-enriched pirfenidone and methods of use thereof
CA3171622A1 (en) * 2020-03-13 2021-09-16 Puretech Lyt 100, Inc. Methods of treating respiratory disease with deupirfenidone

Also Published As

Publication number Publication date
JP2025502023A (ja) 2025-01-24
WO2023133476A1 (en) 2023-07-13
US20240358690A1 (en) 2024-10-31
EP4460305A1 (en) 2024-11-13
MX2024008476A (es) 2024-07-12
EP4460305A4 (en) 2025-12-31
IL314022A (en) 2024-08-01
AU2023205787A1 (en) 2024-06-13
CA3239301A1 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
RU2646447C2 (ru) ПРИМЕНЕНИЕ АНАЛОГА ТЕСТОСТЕРОНА И АГОНИСТА 5-НТ1а ДЛЯ ЛЕЧЕНИЯ СЕКСУАЛЬНОЙ ДИСФУНКЦИИ
AU2025203171A1 (en) A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis
de Man et al. Influence of the proton pump inhibitor esomeprazole on the bioavailability of regorafenib: a randomized crossover pharmacokinetic study
Boettcher et al. Vericiguat in combination with short‐acting nitroglycerin in patients with chronic coronary syndromes: the randomized, phase Ib, VENICE study
KR20240131352A (ko) 듀피르페니돈을 이용한 특발성 폐섬유증을 치료하는 방법
Marbury et al. Pharmacokinetics of oral dexamethasone and midazolam when administered with single‐dose intravenous 150 mg fosaprepitant in healthy adult subjects
Kaski et al. The ESC Handbook on Cardiovascular Pharmacotherapy
Lahu et al. Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N‐oxide
Fernández‐Fradejas et al. Potentially inappropriate prescriptions and potential prescription omissions in older people living with HIV
US20250249001A1 (en) Methods of treating substance use disorder with 4-(3-cyanophenyl)-6-pyridinylpyrimidine mglu5 negative allosteric modulators
Irizarry et al. Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease
Wu et al. Pharmacokinetics of nifedipine‐sustained release tablets in healthy subjects after a single oral administration: bioequivalence analysis and food effects
WO2025038481A1 (en) Vepdegestrant dosage regimen in cyp3a-inducer treatment in cancer
US20250375431A1 (en) Methods of treating idiopathic pulmonary fibrosis with deupirfenidone
Fehintola et al. Nevirapine‐Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV‐Infected Nigerian Adults
HK40114519A (zh) 用氘吡非尼酮治疗特发性肺纤维化的方法
CN118510510A (zh) 用氘吡非尼酮治疗特发性肺纤维化的方法
US20210137903A1 (en) Anti-androgens for the treatment of prostrate cancer
US20250114340A1 (en) Methods of treating interstitial lung diseases and other fibrotic-mediated pulmonary diseases and disorders with deupirfenidone
Schmitt et al. Results of a phase Ib study of SB-121, an investigational probiotic formulation, in participants with autism spectrum disorder
US20240122928A1 (en) Methods For Treating Agitation In Subjects With Mild Cognitive Impairment Or Major Neurocognition Disorder
Gisbert et al. REIMAGINE: A central nervous system basket trial showing safety and efficacy of vafidemstat on aggression in different psychiatric disorders
Alas-Pineda et al. Cardiac Safety of Intranasal Chlorpheniramine: An Exposure-Based Risk Assessment
Rieborn et al. Exploring the Association Between Intra‐Patient Variability in Trough Concentration of Pazopanib and Clinical Outcomes in Renal Cell Carcinoma and Soft Tissue Sarcoma Patients
McCrea et al. Thorough QTc Evaluation and the Safety of Supratherapeutic Doses of Odanacatib in Healthy Subjects

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240703

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application